First QTR on Monday 9, 2015 after hours, page-25

RRM...with the passing of time a lot of questions can be asked about such statements and guidance

But, away from all the noise about Morgan Stanley and back to the basics....CASH RECEIPTS!

Anyone have ane expectations around revenue? I fear it is going to be less than 5 million

Statements like " we expect that existing and future customization programs will continue to represent the majority of our cash receipts this fiscal year. Product shipments from device platforms including prefilled syringes and wearable injectors will also gradually increase this fiscal year to support customer timelines for commercial rollout and clinical drug trials, and become more meaningful as programs advance through the start of fiscal 2017 and beyond.”

So historically the customisation cash flow has been low. No deals in the past 10 months and gettinginto that window that the Depot-Ject guidance will be challenged. "Unilife anticipates the commercial availability of Depot-ject with this therapy after a 12 to 24 month process of customization and regulatory approval for the drug-device combination."

So would want to see some sort or revenue for this if it is going to be commercially available next year! LOL surely we can get a friggin product on the shelf next year!!!!!